C. L. Kline

发表

Par-4 as a potential target for cancer therapy

R. Irby, C. L. Kline, 2013, Expert opinion on therapeutic targets.

From TRAIL to ONC201: Case Study on the Safety Benefit of Developing Targeted Agents Against Cancer-selective Pathways

W. El-Deiry, Amriti R Lulla, Avital Lev, 2018, Early Drug Development.

Delivery of PAR-4 plasmid in vivo via nanoliposomes sensitizes colon tumor cells subcutaneously implanted into nude mice to 5-FU

R. Irby, C. L. Kline, M. Kester, 2009, Cancer biology & therapy.

ISC-4 and Par-4 inhibit colon tumor growth 1 The Akt inhibitor ISC-4 activates Prostate apoptosis response protein-4 and reduces colon tumor growth in a nude mouse model

R. Irby, S. Amin, C. L. Kline, 2011 .

Cancer Therapy : Preclinical The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model

R. Irby, S. Amin, C. L. Kline, 2011 .

The Akt Inhibitor ISC-4 Activates Prostate Apoptosis Response Protein-4 and Reduces Colon Tumor Growth in a Nude Mouse Model

R. Irby, S. Amin, C. L. Kline, 2011, Clinical Cancer Research.

Resistance to TRAIL Pathway-Targeted Therapeutics in Cancer

W. El-Deiry, C. L. Kline, Jessica Wagner, 2017 .

Preliminary observations indicate variable patterns of plasma 5-fluorouracil (5-FU) levels during dose optimization of infusional 5-FU in colorectal cancer patients

W. El-Deiry, J. Liao, C. L. Kline, 2011, Cancer biology & therapy.

Discovery and clinical introduction of first-in-class imipridone ONC201

Neel S. Madhukar, Michael L. Wang, O. Elemento, 2016, Oncotarget.

Single agent and synergistic combinatorial efficacy of first-in-class small molecule imipridone ONC201 in hematological malignancies

U. McDermott, M. Garnett, C. Benes, 2018, Cell cycle.

Overexpression of Prostate Apoptosis Response Protein-4 in Colon Cancer Cells Can Inhibit Metastasis By Upregulating E-cadherin Expression

R. Irby, C. L. Kline, J. Nguyen, 2015 .

The pro-apoptotic protein Prostate Apoptosis Response Protein-4 (Par-4) can be activated in colon cancer cells by treatment with Src inhibitor and 5-FU

R. Irby, C. L. Kline, 2011, Apoptosis.

Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.

E. Messaris, W. El-Deiry, L. Poritz, 2014, Clinical colorectal cancer.

Prostate apoptosis response protein 4 sensitizes human colon cancer cells to chemotherapeutic 5-FU through mediation of an NFκB and microRNA network

Joshua M. Stuart, M. Weirauch, Bryan Frank, 2010, Molecular Cancer.

Dose intensification of TRAIL-inducing ONC201 inhibits metastasis and promotes intratumoral NK cell recruitment

W. El-Deiry, J. Bertino, Lanlan Zhou, 2018, The Journal of clinical investigation.

Primary cell lines: false representation or model system? a comparison of four human colorectal tumors and their coordinately established cell lines.

W. Koltun, R. Irby, L. Poritz, 2010, International journal of clinical and experimental medicine.

Src kinase induces tumor formation in the c‐SRC C57BL/6 mouse

T. Yeatman, R. Engelman, R. Irby, 2008, International journal of cancer.

Personalizing Colon Cancer Therapeutics: Targeting Old and New Mechanisms of Action

W. El-Deiry, C. L. Kline, 2013, Pharmaceuticals.

Small-Molecule NSC59984 Restores p53 Pathway Signaling and Antitumor Effects against Colorectal Cancer via p73 Activation and Degradation of Mutant p53.

W. El-Deiry, D. Dicker, L. Kopelovich, 2015, Cancer research.

ONC201 kills solid tumor cells by triggering an integrated stress response dependent on ATF4 activation by specific eIF2α kinases

W. El-Deiry, D. Dicker, C. L. Kline, 2016, Science Signaling.

Cancer stem cell-related gene expression as a potential biomarker of response for first-in-class imipridone ONC201 in solid tumors

Neel S. Madhukar, O. Elemento, U. McDermott, 2017, PloS one.

Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism

Jessica M. Rusert, Deric M. Park, Neel S. Madhukar, 2018, Clinical Cancer Research.

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

W. El-Deiry, Lanlan Zhou, C. L. Kline, 2018, Journal of Experimental & Clinical Cancer Research.

Role of Dopamine Receptors in the Anticancer Activity of ONC201

W. El-Deiry, D. Dicker, Amriti R Lulla, 2017, Neoplasia.

Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212

C. Benes, W. El-Deiry, Amriti R Lulla, 2017, Cell cycle.

ONC201 Demonstrates Antitumor Effects in Both Triple-Negative and Non–Triple-Negative Breast Cancers through TRAIL-Dependent and TRAIL-Independent Mechanisms

W. El-Deiry, D. Dicker, C. L. Kline, 2017, Molecular Cancer Therapeutics.

Abstract 2942: TRAIL pathway inducer ONC201/TIC10 primes multiple myeloma cells (MM) for apoptosis by downregulating X-linked inhibitor of apoptosis

W. El-Deiry, D. Dicker, Amriti R Lulla, 2015 .

Small Molecule ONC201/TIC10 Induces Caspase-Dependent Apoptosis in Acute Lymphoblastic Leukemia Cells Via Modulation of Bcl-2 and IAP Family Proteins

W. El-Deiry, D. Dicker, Amriti R Lulla, 2014 .

The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity

W. El-Deiry, D. Dicker, C. L. Kline, 2014, Oncotarget.

Regulation and Role of Par-4 in Gastrointestinal Tumors

R. Irby, C. L. Kline, ArunK. Sharma, 2021, Tumor Suppressor Par-4.

Src activity alters α3 integrin expression in colon tumor cells

Thomas L. Olson, R. Irby, C. L. Kline, 2008, Clinical & Experimental Metastasis.

Glucosamine-induced phosphorylation of the alpha-subunit of eukaryotic initiation factor 2 is mediated by the protein kinase R-like endoplasmic-reticulum associated kinase.

C. L. Kline, S. Kimball, L. Jefferson, 2006, The international journal of biochemistry & cell biology.

Anti-tumor effects of ONC201 in combination with VEGF-inhibitors significantly impacts colorectal cancer growth and survival in vivo through complementary non-overlapping mechanisms

W. El-Deiry, Lanlan Zhou, C. L. Kline, 2018, Journal of experimental & clinical cancer research : CR.